                         SEQUENCE LISTING

<110>  ZYMEWORKS INC.
 
<120>  STABILIZED TCR CONSTRUCTS AND METHODS OF USE

<130>  V817599WO

<150>  US 63/128,601
<151>  2020-12-21

<160>  43    

<170>  PatentIn version 3.5

<210>  1
<211>  94
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human TCR alpha chain constant region (TRAC)

<400>  1

Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys 
1               5                   10                  15      


Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr 
            20                  25                  30          


Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr 
        35                  40                  45              


Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala 
    50                  55                  60                  


Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser 
65                  70                  75                  80  


Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser 
                85                  90                  


<210>  2
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human TCR beta chain constant region (TRBC1)

<400>  2

Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro 
1               5                   10                  15      


Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu 
            20                  25                  30          


Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn 
        35                  40                  45              


Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys 
    50                  55                  60                  


Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu 
65                  70                  75                  80  


Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys 
                85                  90                  95      


Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp 
            100                 105                 110         


Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg 
        115                 120                 125             


Ala Asp 
    130 


<210>  3
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human TCR beta chain constant region (TRBC2)

<400>  3

Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro 
1               5                   10                  15      


Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu 
            20                  25                  30          


Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn 
        35                  40                  45              


Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys 
    50                  55                  60                  


Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu 
65                  70                  75                  80  


Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys 
                85                  90                  95      


Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp 
            100                 105                 110         


Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg 
        115                 120                 125             


Ala Asp 
    130 


<210>  4
<211>  95
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human TCR alpha chain constant region (TRAC) including the 
       cysteine residue at position TRAC/128

<400>  4

Asn Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser Lys 
1               5                   10                  15      


Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln Thr 
            20                  25                  30          


Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys Thr 
        35                  40                  45              


Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val Ala 
    50                  55                  60                  


Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn Ser 
65                  70                  75                  80  


Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys 
                85                  90                  95  


<210>  5
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCRalpha hinge sequence

<400>  5

Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr 
1               5                   10                  15  


<210>  6
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCRbeta hinge sequence

<400>  6

Asp Cys Gly Phe Thr Ser 
1               5       


<210>  7
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCRgamma hinge sequence

<400>  7

Asp Val Ile Thr Met Asp Pro Lys Asp Asn Cys Ser Lys Asp Ala Asn 
1               5                   10                  15      


<210>  8
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  TCRdelta hinge sequence

<400>  8

Asp His Val Lys Pro Lys Glu Thr Glu Asn Thr Lys Gln Pro Ser Lys 
1               5                   10                  15      


Ser Cys His Lys Pro Lys 
            20          


<210>  9
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 hinge sequence

<400>  9

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 
1               5                   10                  15  


<210>  10
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG2 hinge sequence

<400>  10

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 
1               5                   10          


<210>  11
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG3-H1 hinge sequence

<400>  11

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 
1               5                   10                  15      


Pro 
    


<210>  12
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG3-H2, -H3 & -H4 hinge sequence

<400>  12

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 
1               5                   10                  15  


<210>  13
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG4 hinge sequence

<400>  13

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro 
1               5                   10          


<210>  14
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgA2 hinge sequence

<400>  14

Val Pro Pro Pro Pro Pro 
1               5       


<210>  15
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 full hinge sequence

<400>  15

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      


Pro Glu Leu Leu Gly Gly 
            20          


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 upper hinge sequence

<400>  16

Glu Pro Lys Ser Cys Asp Lys Thr His Thr 
1               5                   10  


<210>  17
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 core hinge sequence

<400>  17

Cys Pro Pro Cys Pro 
1               5   


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 lower hinge sequence

<400>  18

Ala Pro Glu Leu Leu Gly Gly 
1               5           


<210>  19
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 partial hinge sequence

<400>  19

Glu Pro Lys Ser Cys 
1               5   


<210>  20
<211>  217
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human IgG1 Fc sequence 231-447 (EU-numbering)

<400>  20

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 
1               5                   10                  15      


Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 
            20                  25                  30          


Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 
        35                  40                  45              


Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 
    50                  55                  60                  


Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 
65                  70                  75                  80  


Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 
                85                  90                  95      


Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 
            100                 105                 110         


Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 
        115                 120                 125             


Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 
    130                 135                 140                 


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
145                 150                 155                 160 


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 
                165                 170                 175     


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 
            180                 185                 190         


Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 
        195                 200                 205             


Lys Ser Leu Ser Leu Ser Pro Gly Lys 
    210                 215         


<210>  21
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IgG1 partial hinge sequence

<400>  21

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 
1               5                   10                  15  


<210>  22
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Signal sequence

<400>  22

Met Arg Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Leu Ala 
1               5                   10                  15      


Leu Trp Ala Pro Ala Arg Gly 
            20              


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NY-ESO1 peptide

<400>  23

Ser Leu Leu Met Trp Ile Thr Gln Cys 
1               5                   


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  gp100 peptide

<400>  24

Tyr Leu Glu Pro Gly Pro Val Thr Ala 
1               5                   


<210>  25
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR2a

<400>  25

Ile Arg Ser Asn Glu Arg Glu 
1               5           


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR3a

<400>  26

Ala Thr Asp Gly Ser Thr Pro Met Gln 
1               5                   


<210>  27
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR2b

<400>  27

Ser Trp Ala Gln Gly Asp 
1               5       


<210>  28
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR3b

<400>  28

Ala Ser Ser Trp Gly Ala Pro Tyr 
1               5               


<210>  29
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR3a

<400>  29

Ala Thr Asp Gly Asp Thr Pro Leu Val 
1               5                   


<210>  30
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR3b

<400>  30

Ala Ser Ser His Gly Ala Pro Tyr 
1               5               


<210>  31
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR2b

<400>  31

Ser Trp Gly Thr Gly Asp 
1               5       


<210>  32
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR2b

<400>  32

Ser Trp Ala Val Gly Asn 
1               5       


<210>  33
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-gp100 CDR3b

<400>  33

Ala Ser Ser Ile Gly Gly Pro Tyr 
1               5               


<210>  34
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR2a

<400>  34

Ile Thr Pro Trp Gln Arg Glu 
1               5           


<210>  35
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR3a

<400>  35

Ala Val Arg Pro Leu Leu Asp Gly Thr Tyr Ile Pro Thr 
1               5                   10              


<210>  36
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR2b

<400>  36

Ser Val Ala Ile Gln Thr 
1               5       


<210>  37
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR3b

<400>  37

Ala Ser Ser Tyr Leu Gly Asn Thr Gly Glu Leu Phe 
1               5                   10          


<210>  38
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR2a

<400>  38

Ile Gln Ser Ser Gln Arg Glu 
1               5           


<210>  39
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR3a

<400>  39

Ala Val Arg His Thr Ser Asn Gly Tyr Phe Pro Pro Thr 
1               5                   10              


<210>  40
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR2b

<400>  40

Ser Val Gly Ala Gly Thr 
1               5       


<210>  41
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR2a

<400>  41

Ile Ser Pro Trp Gln Arg Glu 
1               5           


<210>  42
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-NY-ESO1 CDR3b

<400>  42

Ala Ser Ser Tyr Val Gly Asp Thr Gly Glu Leu Phe 
1               5                   10          


<210>  43
<211>  130
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human TCR beta chain constant region (TRBC1) including Cys -> Ala
       mutation at position 85.1

<400>  43

Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro 
1               5                   10                  15      


Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu 
            20                  25                  30          


Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser Trp Trp Val Asn 
        35                  40                  45              


Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys 
    50                  55                  60                  


Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Ala Leu Ser Ser Arg Leu 
65                  70                  75                  80  


Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys 
                85                  90                  95      


Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp 
            100                 105                 110         


Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg 
        115                 120                 125             


Ala Asp 
    130 


